A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies

Conditions:   Hematologic Malignancy;   Leukemia;   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, T-Cell;   Lymphoma, Non-Hodgkin Intervention:   Biological: CAR-37 T cells Sponsor:   Marcela V. Maus, M.D.,Ph.D. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials